Procter & Gamble Health

    PGHL
    Pharma
    ₹5,342.00
    Price as of 3 Oct 2026, 1:02 pm IST

    Market cap ₹8,867 Cr

    P/E
    24.85
    Day range
    ₹5,325.00 – ₹5,534.00
    52-week range
    ₹4,707.00 – ₹6,975.00
    Volume
    8,710
    Open
    ₹5,515.00
    Prev close
    ₹5,563.00

    No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.

    PGHL in NSE indices and F&O

    Research profile

    Derived metrics

    Earn. yield
    4.0%

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 66 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.32 L Cr35.715.1814.8%21.0%29.0%0.06+10.5%
    Divi's LaboratoriesDIVISLAB₹2.46 L Cr84.0414.6616.2%22.0%41.0%0.00+27.8%
    Torrent PharmaTORNTPHARM₹1.81 L Cr76.3419.2226.8%15.0%34.0%1.79+54.8%
    Apollo HospitalsAPOLLOHOSP₹1.17 L Cr55.8713.6022.6%17.0%16.0%0.90+20.6%
    Zydus LifesciencesZYDUSLIFE₹1.14 L Cr25.514.2620.1%21.0%24.0%0.46+22.0%
    CiplaCIPLA₹1.09 L Cr32.263.2011.8%15.0%17.0%0.02+2.3%
    Laurus LabsLAURUSLABS₹1.07 L Cr98.0220.2018.2%18.0%32.0%0.48+29.0%
    Procter & Gamble HealthPGHL₹8,867 Cr24.85——————
    Sector median₹26,237 Cr45.277.0515.5%17.0%24.5%0.18+20.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Quarterly results

    Consolidated
    Quarterly income statement on a consolidated basis, most recent first
    MetricSept 2019Jun 2019Mar 2019Dec 2018
    Revenue₹225.17 Cr₹233.63 Cr₹231.03 Cr₹204.39 Cr
    Other incomeNot available — not reported in this filingNot available — not reported in this filingNot available — not reported in this filingNot available — not reported in this filing
    Total incomeNot available — not reported in this filingNot available — not reported in this filingNot available — not reported in this filingNot available — not reported in this filing
    Total expensesNot available — not reported in this filingNot available — not reported in this filingNot available — not reported in this filingNot available — not reported in this filing
    Profit before taxNot available — not reported in this filingNot available — not reported in this filingNot available — not reported in this filingNot available — not reported in this filing
    Profit after tax₹0.00₹0.00₹0.00₹715.34 Cr
    Basic EPSNot available — not reported in this filingNot available — not reported in this filingNot available — not reported in this filingNot available — not reported in this filing
    Diluted EPSNot available — not reported in this filingNot available — not reported in this filingNot available — not reported in this filingNot available — not reported in this filing
    Debt to equityNot available — not reported in this filingNot available — not reported in this filingNot available — not reported in this filingNot available — not reported in this filing
    Debt service coverageNot available — not reported in this filingNot available — not reported in this filingNot available — not reported in this filingNot available — not reported in this filing

    Corporate actions

    No dividends, splits or bonuses recorded for this company yet.
    FAQ

    Procter & Gamble Health: common questions

    Answered from the figures on this page.

    Procter & Gamble Health last traded at ₹5,342.00 (NSE, as of 3 Oct 2026). The last session moved it down 3.97%.

    Procter & Gamble Health is valued at about ₹8,867 crore (NSE, as of 3 Oct 2026).

    Procter & Gamble Health trades at a price-to-earnings ratio of 24.85 (NSE, as of 3 Oct 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Procter & Gamble Health has traded between ₹4,707.00 and ₹6,975.00 over the past 52 weeks, to 3 Oct 2026. It is currently 28% of the way up that range.

    Procter & Gamble Health (PGHL) is classified under Pharma on this site's screener.